← Leaderboards
Matthew Charles Mulvey
Sequella, Inc.
$684,296
Attributed
$684,296
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $244.3K · FY2008–13$250K$187.5K$125K$62.5K$0
'08
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$684,296 · 2
By mechanism
R21$439,950 · 1
R43$244,346 · 1
Top collaborators
No co-investigators on record.
Most similar at Sequella, Inc.
Same institution · by research overlap
- Leo Einck$3,287,911
- Gary Horwith$261,175
Others in their field
Top investigators on “Prevent”
- Lawrence Corey · Fred Hutchinson Cancer Center$609,181,782
- Jeffrey P Krischer · University Of South Florida$605,511,231
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$530,065,238
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$499,311,118
- David Heimbrook · Leidos Biomedical Research, Inc.$496,394,926
Research focus
PreventTechnologyInfectionPharmaceutical PreparationsRifampinSputumDetectionGenus MycobacteriumMycobacteriophagesNucleic AcidsReporterResistanceSiteSpecimenAntibiotic SusceptibilityComplexDrug ResistanceEnsureIsoniazidMulti-Drug ResistanceBacteriophagesMycobacterium TuberculosisBaseTuberculosis
Grant awards (3)
A Kit for Rapid AST of Mycobacterium tuberculosis from Clinical Samples$231,000
R21 · FY2013 · AI · contact PI
A Kit for Rapid AST of Mycobacterium tuberculosis from Clinical Samples$208,950
R21 · FY2012 · AI · contact PI
Development of a phage-based nucleic acid amplification diagnostic for the rapid$244,346
R43 · FY2008 · AI · contact PI